Core Insights - The 28th CSCO Annual Meeting was held in Jinan, Shandong, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Hysco Clinical Oncology Research Foundation, featuring 75 academic sessions and around 1,500 expert speakers, including over 30 international experts from 15 countries [1][2] Group 1: Academic Collaboration - CSCO aims to deepen international cooperation in cancer prevention and treatment, with dialogues planned with high-level representatives from ESMO and other organizations to explore new opportunities [2] - ASCO expressed its commitment to maintaining a strong collaborative relationship with CSCO, emphasizing joint scientific meetings and various initiatives to enhance global oncology development [3] Group 2: Recognition and Awards - CSCO awarded the Annual Achievement Award to three scholars for their significant contributions to clinical oncology, highlighting the importance of innovation and impact in the field [4] - Ten outstanding research papers were recognized, focusing on treatment strategies, new drug development, biomarker exploration, and real-world data analysis, showcasing the depth and innovation of Chinese oncology research [4] Group 3: Academic Content and Innovation - The conference featured 75 academic sessions, emphasizing original research and evidence-based medicine, with a focus on new therapies like ADC and CAR-T/CAR-NK, and addressing major cancer types through AI-focused sessions [6] - The meeting also highlighted the management of cancer as a chronic disease, with a focus on patient quality of life and long-term survival, alongside the release of new clinical guidelines [6] Group 4: Future Directions - The theme of the conference, "Standardized Diagnosis and Treatment, Innovative Leadership," included 530 academic reports and 196 oral presentations, aiming to translate research achievements into clinical practice [7] - The event serves as a key platform for the Chinese oncology community to showcase achievements and foster collaboration, ultimately enhancing cancer prevention and treatment standards in China [7]